{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-228289","form_type":"8-K","ticker":"FDMT","cik":"0001650648","company_name":"4D Molecular Therapeutics, Inc.","filed_at":"2025-10-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.046065+00:00","generated_at":"2026-05-17T04:56:11.043553+00:00","sec_items":["5.02","5.03","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"4D Molecular Therapeutics appoints Ashoo Gupta as Principal Financial Officer","bullets":["Ashoo Gupta appointed Principal Financial Officer and Principal Accounting Officer effective September 30, 2025.","Mr. Gupta previously served as VP Finance & Controller at 4D since June 2024.","Prior roles include VP Finance and Corporate Controller at Kyverna Therapeutics and Executive Director of Accounting at Myovant Sciences.","Board amended and restated bylaws to update advance notice procedures for business and director nominations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-228289","json":"https://secwatch.observer/filing/0001193125-25-228289.json","markdown":"https://secwatch.observer/filing/0001193125-25-228289.md","text":"https://secwatch.observer/filing/0001193125-25-228289.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525228289/0001193125-25-228289-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525228289/fdmt-20250930.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:56:11.043553+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"79cb864374a09df6ca1c43b3d89c81803a57b59c","claim":"4D Molecular Therapeutics, Inc.: Board amended and restated Bylaws to update advance notice procedures for business brought before a meeting and for nominations of directors (effective 2025-09-30).","evidence_excerpt":"On September 30, 2025, the Board amended and restated the Company’s current amended and restated bylaws (the “Amended and Restated Bylaws”). The Amended and Restated Bylaws were amended to, among other revisions, update the advance notice procedures for business brought before a meeting and update the advance notice procedures for nominations of directors.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312525228289/0001193125-25-228289-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"bylaw amendment"},{"label":"Effective","value":"2025-09-30"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}